Is T-bet a potential therapeutic target in multiple sclerosis?

Journal of Interferon and Cytokine Research

Volumn 34, Issue 8, 2014, Pages 623-632

  Racke, Michael K ^a   Yang, Yuhong ^a   Lovett Racke, Amy E ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; MICRORNA; MYELIN; TRANSCRIPTION FACTOR T BET; FINGOLIMOD; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; MONOCLONAL ANTIBODY; NATALIZUMAB; PROPANEDIOL DERIVATIVE; SPHINGOSINE; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ADOPTIVE TRANSFER; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL THERAPY; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG DEVELOPMENT; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG DISCOVERY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FUMARATES; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE; T-BOX DOMAIN PROTEINS; TH17 CELLS;

EID: 84905407583     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0020     Document Type: Review

References (99)

1. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. 2007. Interleukins 1b and 6 but not transforming growth factor-b are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942-949.
2. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. 1990. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718-721.
3. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE. 1989. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 124:132-143.
4. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al. 2009. Human memory FOXP3 Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A 106:8635-8640.
5. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA, Jr. 1993. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177:57-68.
6. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N. 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7:929-936.
7. Becher B, Durell BG, Noelle RJ. 2002. Experimental autoimmune encephalitis and inflammation in the absence of inter-leukin-12. J Clin Invest 110:493-497.
8. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167-1175.
9. Bettelli B, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238.
10. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchroo VK. 2004. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalo-myelitis. J Exp Med 200:79-87.
11. Brucklacher-Waldert V, Steinbach K, Lioznov M, Kolster M, Holscher C, Tolosa E. 2009. Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression. J Immunol 183:5494-5501.
12. Burns J, Bartholomew B, Lobo S. 1999. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol 45:33-39.
13. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735.
14. Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, et al. 2001. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 108:739-747.
15. Chu CQ, Wittmer S, Dalton DK. 2000. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 192:123-128.
16. Crawford MP, Yan X, Ortega S, Mehta RS, Hewitt RE, Price DA, Stastny P, Douek DC, Koup RA, Racke MK, Karandikar NJ. 2004. High prevalence of autoreactive neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103:4222-4231.
17. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744-748.
18. Drulovic J, Savic E, Pekmezovic T, Mesaros S, Stojsavljevic N, Dujmovic-Basuroski I, et al. 2009. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?. J Neuroimmunol 215:90-95.
19. Duhen R, Glatigny S, Arbelaez CA, Blair TC, Oukka M, Bettelli E. 2013. Cutting edge: the pathogenicity of IFN-g-producing Th17 cells is independent of T-bet. J Immunol 190:4478-4482.
20. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellina P, Ferrero B, Eid P, Novelli F. 2009. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 65:499-509.
21. Elhofy A, Depaolo RW, Lira SA, Lukacs NW, Karpus WJ. 2009. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. J Neuroimmunol 213:91-99.
22. Farrar JD, Murphy KM. 2000. Type I interferons and T helper development. Immunol Today 21:484-489.
23. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, Murphy KM. 2000. Selective loss of type I interferon-induced Stat4 activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol 1:65-69.
24. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, et al. 1996. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156:5-7.
25. Fitzgerald DC, Ciric B, Touil T, Harle H, Grammatikopolou J, Das Sarma J, Zhang G-X, Rostami A. 2007. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 179:3268-3275.
26. Frohman EM, Racke MK, Raine CS. 2006. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 354:942-955.
27. Ghoreschi K, Brück J, Weigert C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Valtcheva N, Alexander E, Feil S, Reil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Röcken M. 2011. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291-2303.
28. Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK, Lovett-Racke AE. 2007. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 178:1341-1348.
29. Gran B, Zhang GX, Yu S, Li J, Chen XH, Ventura ES, et al. 2002. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 169:7104-7110.
30. Grifka-Walk HM, Lalor SJ, Segal BM. 2013. Highly polarized Th17 cells induce EAE via a T-bet independent mechanism. Eur J Immunol 43:2824-2831.
31. Guerau-de-Arellano M, Alder H, Ozer HG, Lovett-Racke AE, Racke MK. 2012. miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol 248:32-39.
32. Guerau-de-Arellano M, Smith KM, Godlewski J, Liu Y, Winger R, Lawler SE, Whitacre CC, Racke MK, Lovett-Racke AE. 2011. microRNA dysregulation in multiple sclerosis favors pro-inflammatory T cell-mediated autoimmunity. Brain 134: 3575-3586.
33. Gyülvészi G, Haak S, Becher B. 2009. IL-23-driven encephalo-tropism and TH17 polarization during CNS-inflammation in vivo. Eur J Immunol 39:1864-1869.
34. Haak S, Croxford AL, Kreymborg K, Heppner FL, Pouly S, Becher B, et al. 2009. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 119:61-69.
35. Heremans H, Dillen C, Groenen M, Martens E, Billiau A. 1996. Chronic relapsing experimental autoimmune encephalo-myelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur J Immunol 26:2393-2398.
36. Huss DJ, Winger RC, Peng H, Yang Y, Racke MK, Lovett-Racke AE. 2010. TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J Immunol 184:5628-5636.
37. Huss DJ, Winger RC, Yang Y, Guerau M, Racke MK, Lovett-Racke AE. 2011. TGF-b signaling via smad4 drives IL-10 production in effector Th1 cells and reduces host cell recruitment in EAE. Eur J Immunol 41:2987-2996.
38. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Taka-kura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J. 2005. Intrathecal activation of the IL-17/IL-8 axis in opti-cospinal multiple sclerosis. Brain 128:988-1002.
39. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. 2006. The orphan nuclear receptor ROR-gammat directs the differentiation program of proin-flammatory IL-17 + T helper cells. Cell 126:1121-1133.
40. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. 2013. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 13:154-157.
41. Karandikar NJ, Crawford MP, Ratts RB, Brenchley JM, Am-brozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA, Racke MK. 2002. Glatiramer acetate (Copaxone) therapy induces CD8 + T cell responses in patients with multiple sclerosis. J Clin Invest 109:641-649.
42. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A. 2009. Preferential recruitment of inter-feron-gamma-expressing TH 17 cells in multiple sclerosis. Ann Neurol 66:390-402.
43. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. 2008. Human CD25high Foxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112: 2340-2352.
44. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. Int Immunol 177:566-573.
45. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M, VK Kuchroo. 2007. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448:484-487.
46. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ. 1999. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 53:1692-1697.
47. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. 2008. IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205:1535-1541.
48. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240.
49. Lee Y, Awasthi A, Yosef N, Quintana FJ, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, Sobel RA, Regev A, Kuchroo VK. 2012. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13:991-999.
50. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. 2002. Gene microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune enceph-alomyelitis. Nat Med 8:500-508.
51. Longbrake EE, Racke MK. 2009. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 9:319-321.
52. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis J, Diab A, Drew PD, Racke MK. 2004b. PPARa agonists as therapy for autoimmune disease. J Immunol 172:5790-5798.
53. Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, et al. 2004a. Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 21:719-731.
54. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. 1998. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 101:725-730.
55. Lublin FD, Knobler RL, Kalman B, Goldhaber M, Marini J, Perrault M, et al. 1993. Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 16:267-274.
56. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, et al. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177:1199-1204.
57. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. 1999. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5:101-104.
58. McDonald AH, Swanborg RH. 1988. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J Immunol 140:1132-1138.
59. Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M. 1998. In-terleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur J Immunol 28:1727-1737.
60. Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173.
61. Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A, Rajewsky K. 2005. Aberrant T cell differentiation in the absence of Dicer. J Exp Med 202:261-269.
62. Nath N, Prasad R, Giri S, Singh AK, Singh I. 2006. T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology 118:384-391.
63. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10:111-122.
64. O'Connor RA, Cambrook H, Huettner K, Anderton SM. 2013. T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease. Eur J Immunol 43:2818-2823.
65. Olsson T, Zhi WW, Hojeberg B, Kostulas V, Jiang YP, Anderson G, et al. 1990. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 86:981-985.
66. Panitch HS, Hirsch RL, Haley AS, Johnson KP. 1987. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893-895.
67. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. 2000. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 165:1641-1651.
68. Peng H, Guerau-de-Arellano, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, Lovett-Racke AE, Racke MK. 2012. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kB (NF-kB) and extracellular signal-regulated kinase 1 and 2 (ERK 1/2) and mitogen stress activated kinase 1 (MSK1) signaling. J Biol Chem 287:28017-28026.
69. Pettinelli CB, McFarlin DE. 1981. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt1+2-T lymphocytes. J Immunol 127: 1420-1423.
70. Pouly S, Becher B, Blain M, Antel JP. 2000. Interferon-gamma modulates human oligodendrocyte susceptibility to Fasmediated apoptosis. J Neuropathol Exp Neurol 59:280-286.
71. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al. 1994. Cytokine induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180:1961-1966.
72. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. 1995. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 154:450-458.
73. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. 1991. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta1. J Immunol 146:3012-3017.
74. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovi-Plese S. 2009. IFN-beta inhibits human Th17 differentiation. J Immunol 183:5418-5427.
75. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F. 2009. CC chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10:514-523.
76. Revel M, Chebath J, Mangelus M, Harroch S, Moviglia GA. 1995. Antagonism of interferon-beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult Scler (Suppl. 1) 1:S5-S11.
77. Rivers TM, Schwentker FF. 1935. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 61:689-702.
78. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo controlled, randomised, doseranging study. Lancet Neurol 7:796-804.
79. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. Widespread changes in protein synthesis induced by microRNAs. Nature 455:58-63.
80. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM. 2008. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180:214-221.
81. Skurkovich S, Boiko A, Beliaeva I, Buglak A, Alekseeva T, Smirnova N, Kulakova O, Tchechonin V, Guriva O, Deorina T, Favorova OO, Skurkovic B, Gusev E. 2001. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler 7:277-284.
82. Smith KM, Guerau-de-Arellano M, Costinean S, Williams JL, Bottoni A, Mavrikis Cox G, Satoskar AR, Croce CM, Racke MK, Lovett-Racke AE, Whitacre CC. 2012. miR29ab1-deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol 189:1567-1576.
83. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. 2008. Differential regulation of central nervous system auto-immunity by T(H)1 and T(H)17 cells. Nat Med 14:337-342.
84. Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK. 2006b. Altered CD4:CD8 T cell ratios in cerebrospinal fluid of natalizumab-treated multiple sclerosis patients. Arch Neurol 63:1383-1387.
85. Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK. 2006a. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59:743-747.
86. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, et al. 1991. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 21:1461-1468.
87. Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, et al. 2000. Requirement for RORgamma in thy-mocyte survival and lymphoid organ development. Science 288:2369-2373.
88. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomy-elitis. J Exp Med 203:1685-1691.
89. Vartanian T, Li Y, Zhao M, Stefansson K. 1995. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1:732-743.
90. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179-189.
91. Villares R, Cadenas V, Lozano M, Almonacid L, Zaballos A, Martinez AC, Varona R. 2009. CCR6 regulates EAE patho-genesis by controlling regulatory CD4+ T-cell recruitment to target tissues. Eur J Immunol 39:1671-1681.
92. Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, McFarland HF. 1993. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Au-toimmunity 15:137-143.
93. Waldburger KE, Hastings RC, Schaub RG, Goldman SJ, Leonard JP. 1996. Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am J Pathol 148:375-382.
94. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R. 2001. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 50:349-357.
95. Wang X, Chen M, Wandinger KP, Williams G, Dhib-Jalbut S. 2000. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 165:548-557.
96. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. 1996. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligoden-drocyte glycoprotein-induced autoimmune encephalomyeli-tis. J Immunol 157:3223-3227.
97. Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, et al. 2009. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med 206:1549-1564.
98. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Stein-man L, Karin N. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 56:63-66.
99. Yura M, Takahashi I, Serada M, Koshio T, Nakagami K, Yuki Y, et al. 2001. Role of MOG stimulated Th1 type "light up" (GFP + ) CD4 + T cells for the development of experimental autoimmune encephalomyelitis (EAE). J Autoimmun 17:17-25.